{
    "clinical_study": {
        "@rank": "90646", 
        "arm_group": [
            {
                "arm_group_label": "1 Empagliflozin/Metformin (T)", 
                "arm_group_type": "Experimental", 
                "description": "fixed-dose-combination tablet, oral with 240 ml water under fasted conditions"
            }, 
            {
                "arm_group_label": "2 Empagliflozin/Metformin (T)", 
                "arm_group_type": "Experimental", 
                "description": "fixed-dose-combination tablet, oral with 240 ml water under fed conditions"
            }, 
            {
                "arm_group_label": "3 Empagliflozin + Metformin (R)", 
                "arm_group_type": "Experimental", 
                "description": "tablets, oral with 240 ml water under fasted conditions"
            }, 
            {
                "arm_group_label": "4 Empagliflozin + Metformin (R)", 
                "arm_group_type": "Experimental", 
                "description": "tablets, oral with 240 ml water under fed conditions"
            }, 
            {
                "arm_group_label": "5 Empagliflozin/Metformin (T)", 
                "arm_group_type": "Experimental", 
                "description": "fixed-dose-combination tablet, oral with 240 ml water under fed conditions"
            }, 
            {
                "arm_group_label": "6 Empagliflozin + Metformin (R)", 
                "arm_group_type": "Experimental", 
                "description": "tablets, oral with 240 ml water under fed conditions"
            }
        ], 
        "brief_summary": {
            "textblock": "Bioequivalence of an empagliflozin/metformin (FDC) tablet compared with single tablets of\n      two strength of empagliflozin and metformin (Part I) under fasted and under fed conditions\n      and bioequivalence of empagliflozin/metformin (FDC) tablet compared with single tablets\n      empagliflozin and metformin under fed conditions (Part II)."
        }, 
        "brief_title": "Equivalence of Resorption of Empagliflozin/Metformin Administered as Combination Tablet Compared With Empagliflozin/Metformin as Single Tablets Administered Together", 
        "completion_date": {
            "#text": "May 2013", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n        1. Healthy male and female subjects\n\n        Exclusion criteria:\n\n        1. Any relevant deviation from healthy conditions"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "50 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "48", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "March 13, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01811953", 
            "org_study_id": "1276.8", 
            "secondary_id": "2012-005156-42"
        }, 
        "intervention": [
            {
                "arm_group_label": "4 Empagliflozin + Metformin (R)", 
                "description": "medium dose oral administration", 
                "intervention_name": "Empagliflozin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "4 Empagliflozin + Metformin (R)", 
                "description": "oral administration", 
                "intervention_name": "Metformin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "6 Empagliflozin + Metformin (R)", 
                "description": "low dose of Empagliflozin oral administration", 
                "intervention_name": "Empagliflozin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "5 Empagliflozin/Metformin (T)", 
                "description": "low dose of Empagliflozin", 
                "intervention_name": "Empagliflozin/Metformin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "6 Empagliflozin + Metformin (R)", 
                "description": "oral administration", 
                "intervention_name": "Metformin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "2 Empagliflozin/Metformin (T)", 
                "description": "medium dose of Empagliflozin oral administration", 
                "intervention_name": "Empagliflozin/Metformin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "3 Empagliflozin + Metformin (R)", 
                "description": "medium dose oral administration", 
                "intervention_name": "Empagliflozin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "3 Empagliflozin + Metformin (R)", 
                "description": "oral administration", 
                "intervention_name": "Metformin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "1 Empagliflozin/Metformin (T)", 
                "description": "medium dose of Empagliflozin oral administration", 
                "intervention_name": "Empagliflozin/Metformin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Metformin"
        }, 
        "lastchanged_date": "July 10, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Biberach", 
                    "country": "Germany"
                }, 
                "name": "1276.8.1 Boehringer Ingelheim Investigational Site"
            }
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "6", 
        "official_title": "Bioequivalence of Empagliflozin/Metformin Fixed Dose Combination Tablets Compared to Single Tablets Administered Together in Healthy Male and Female Volunteers Under Fed and Fasted Conditions (an Open-label, Randomised, Single-dose, Crossover Study)", 
        "overall_official": {
            "affiliation": "Boehringer Ingelheim", 
            "last_name": "Boehringer Ingelheim", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "May 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity", 
                "safety_issue": "No", 
                "time_frame": "up to 72 hours"
            }, 
            {
                "measure": "maximum measured concentration of the analyte in plasma", 
                "safety_issue": "No", 
                "time_frame": "up to 72 hours"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01811953"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point", 
            "safety_issue": "No", 
            "time_frame": "up to 72 hours"
        }, 
        "source": "Boehringer Ingelheim", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Boehringer Ingelheim", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}